Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Number of Biopsies With False Positives Between Biopsy Tissue and Intraprostatic MRI
研究概览
简要总结
This clinical research study tests the Uronav system. Patients with prostate cancer will be asked to take part in this study.
Uronav system is an investigational device that is used on this study to help place markers in the patient. These are called fiducial markers and they are placed in the patient to help plan radiation treatment. Radiation therapy treatment will be planned by the treating physician and will not be experimental or part of this research study.
This study will also test the similarities and differences of biopsy tissue structures and the findings from the intraprostatic MRI (internally guided MRI).
详细描述
Study Objectives
Specific Aim 1: Evaluate final pathology post-operatively for histopathology confirmation of multiparametric MRI targets detected during treatment planning. This will be accomplished by using transperineal biopsies obtained prior to interstitial brachytherapy during the procedure, while under anesthetic just prior to the placement of the brachytherapy needles and sources.
Specific Aim 2: Evaluate the ability of the Uronav system in a transperineal setting to guide biopsy needle placement using the electromagnetic guidance system and transperineal ultrasound probe stabilization device and stepper.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must have histopathology confirmed prostate cancer that is Gleason score ≤7(4+3) clinical stage ≤ T2bN0M0 with a Prostate-specific antigen (PSA) below 15 ng/mL.
- •Patients must have MRI findings reporting intraprostatic lesions suspicious for malignancy.
- •Patient must not have had any prior treatment for prostate cancer
- •Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
- •Subjects must have an International Prostate Symptom Score of ≤
- •Subjects must have the ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Gleason score of ≥ 8(4+4)
- •PSA ≥ 15 ng/mL.
- •Clinical stage >T2b or evidence of nodal
- •Patients who are on anticoagulants or high dose aspirin therapy that cannot be safely stopped for greater than 10 days prior to treatment should be excluded to limit increased risk for urinary obstruction.
- •Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •HIV-positive patients on combination antiretroviral therapy are ineligible because of the unlikely risk of prostate cancer being life threatening in this population.
结局指标
主要结局
Number of Biopsies With False Positives Between Biopsy Tissue and Intraprostatic MRI
时间窗: Within 15 days of screening
Number of biopsies with false positives between biopsy tissue and intraprostatic MRI (positive predictive values of MRI)
Number of Participants Who Had Biopsies With True Positives Between Biopsy Tissue and Intraprostatic MRI
时间窗: Within 15 days of screening
Number of participants who had biopsies with true positives between biopsy tissue and intraprostatic MRI (sensitivity of the intraprostatic MRI)
Number of Biopsies With True Negatives Between Biopsy Tissue and Intraprostatic MRI
时间窗: Within 15 days of screening
Number of biopsies with true negatives between biopsy tissue and intraprostatic MRI (specificity of the intraprostatic MRI)
Number of Biopsies With False Negatives Between Biopsy Tissue and Intraprostatic MRI
时间窗: Within 15 days of screening
Number of biopsies with false negatives between biopsy tissue and intraprostatic MRI (negative predictive values of MRI)
次要结局
- Number of Participants With Infections Within 30 Days(Up to 30 days post biopsy)
- Dosimetric Coverage of Brachytherapy Implant Described by Mean V100 (% Volume)(Up to 15 days after screening)
- Dosimetric Coverage of Targeted Lesion Described by Mean D90 (%Rx)(Up to 15 days after screening)
- Number of Hospitalizations Within 30 Days(Up to 30 days post biopsy)
- Dosimetric Coverage of Brachytherapy Implant Described by Mean D90 (% Rx)(Up to 15 days after screening)
- Number of Participants Who Had Successful Completion of Transperineal Biopsy Procedure(Up to 15 days after screening)
- Dosimetric Coverage of Targeted Lesion Described by Mean V100 (% Volume)(Up to 15 days after screening)